Personalized immune monitoring could transform liver transplant care

NCT ID NCT06063213

Ongoing Knowledge-focused Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new method to monitor the immune system after a liver transplant. The goal is to see if a personalized approach can help doctors adjust immunosuppression drugs more accurately, reducing the risk of rejection or infection. Forty adult liver transplant recipients will be followed for six months to track episodes of rejection and infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Phenotypic personalized medicine (PPM) protocol
What this could lead to: If successful, this could lead to a more personalized approach to managing immunosuppression after liver transplant, potentially reducing rejection and infection.
What could go wrong: This is a small, early-stage study with only 40 participants, so results may not apply to all transplant patients. The approach is still being tested and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSPLANT COMPLICATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease related to transplantation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSPLANT COMPLICATION

Contacts and locations

Locations

University of Florida

Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.